Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression
Top Cited Papers
Open Access
- 26 June 2012
- journal article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 72 (5), 728-735
- https://doi.org/10.1136/annrheumdis-2012-201381
Abstract
To determine the prevalence of upregulation of interferon (IFN) type I inducible genes, the so called ‘IFN type I signature’, in CD14 monocytes in 69 patients with primary Sjögren's syndrome (pSS) and 44 healthy controls (HC) and correlate it with disease manifestations and expression of B cell activating factor (BAFF). Expression of IFI44L, IFI44, IFIT3, LY6E and MX1 was measured using real time quantitative PCR in monocytes. Expression values were used to calculate IFN type I scores for each subject. pSS patients positive for the IFN type I signature (IFN score≥10) and patients negative for the signature (IFN score<10) were then compared for clinical disease manifestations and BAFF expression. A bioassay using a monocytic cell line was performed to study whether BAFF mRNA expression was inducible by IFN type I activity in serum of patients with pSS. An IFN type I signature was present in 55% of patients with pSS compared with 4.5% of HC. Patients with the IFN type I signature showed: (a) higher EULAR Sjögren's Syndrome Disease Activity Index scores; higher anti-Ro52, anti-Ro60 and anti-La autoantibodies; higher rheumatoid factor; higher serum IgG; lower C3, lower absolute lymphocyte and neutrophil counts; (b)higher BAFF gene expression in monocytes. In addition, serum of signature-positive patients induced BAFF gene expression in monocytes. The monocyte IFN type I signature identifies a subgroup of patients with pSS with a higher clinical disease activity together with higher BAFF mRNA expression. Such patients might benefit from treatment blocking IFN type I production or activity.Keywords
This publication has 35 references indexed in Scilit:
- Peripheral blood gene expression profiling in Sjögren's syndromeGenes & Immunity, 2009
- Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseasesArthritis Research & Therapy, 2009
- Systemic increase in type I interferon activity in Sjögren's syndrome: A putative role for plasmacytoid dendritic cellsEuropean Journal of Immunology, 2008
- Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndromeProceedings of the National Academy of Sciences, 2006
- Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjectsArthritis & Rheumatism, 2005
- Activation of the type I interferon system in primary Sjögren's syndrome: A possible etiopathogenic mechanismArthritis & Rheumatism, 2005
- TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITYAnnual Review of Immunology, 2005
- Links between innate and adaptive immunity via type I interferonCurrent Opinion in Immunology, 2002
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- Type I IFNs Enhance the Terminal Differentiation of Dendritic CellsThe Journal of Immunology, 1998